These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 24403566)
1. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158 [TBL] [Abstract][Full Text] [Related]
4. RETINAL VASCULAR DEVELOPMENT WITH 0.312 MG INTRAVITREAL BEVACIZUMAB TO TREAT SEVERE POSTERIOR RETINOPATHY OF PREMATURITY: A Longitudinal Fluorescein Angiographic Study. Lorenz B; Stieger K; Jäger M; Mais C; Stieger S; Andrassi-Darida M Retina; 2017 Jan; 37(1):97-111. PubMed ID: 27454223 [TBL] [Abstract][Full Text] [Related]
5. Aggressive Posterior Retinopathy of Prematurity Treated with Intravitreal Bevacizumab: Late Period Fluorescein Angiographic Findings. Perente I; Eris E; Seymen Z; Cevik SG; Bekmez S Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1141-1146. PubMed ID: 30895452 [TBL] [Abstract][Full Text] [Related]
6. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY. Harper CA; Wright LM; Young RC; Read SP; Chang EY Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248 [TBL] [Abstract][Full Text] [Related]
8. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up. Isaac M; Tehrani N; Mireskandari K; Eye (Lond); 2016 Mar; 30(3):333-41. PubMed ID: 26869159 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal injection of bevacizumab for retinopathy of prematurity. Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819 [TBL] [Abstract][Full Text] [Related]
10. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression. Vural A; Ekinci DY; Onur IU; Hergünsel GO; Yiğit FU Int Ophthalmol; 2019 Oct; 39(10):2267-2274. PubMed ID: 30604251 [TBL] [Abstract][Full Text] [Related]
11. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy. Mintz-Hittner HA; Geloneck MM; Chuang AZ Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619 [TBL] [Abstract][Full Text] [Related]
12. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis. Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024 [TBL] [Abstract][Full Text] [Related]
13. Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP. Ekinci DY; Vural AD; Bayramoglu SE; Onur IU; Hergunsel GO Int Ophthalmol; 2019 Dec; 39(12):2697-2705. PubMed ID: 30830544 [TBL] [Abstract][Full Text] [Related]
14. Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I. Padhi TR; Das T; Rath S; Pradhan L; Sutar S; Panda KG; Modi R; Jalali S Eye (Lond); 2016 Mar; 30(3):392-9. PubMed ID: 26584796 [TBL] [Abstract][Full Text] [Related]
15. [Fluorescence Angiography-assisted Management of Recurrences in Aggressive Posterior Retinopathy of Prematurity (APROP) after Intravitreal Monotherapy with 0.312 mg Bevacizumab]. Andrassi-Darida M; Mais C; Stieger K; Lorenz B Klin Monbl Augenheilkd; 2020 Dec; 237(12):1468-1476. PubMed ID: 31770787 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity. Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247 [TBL] [Abstract][Full Text] [Related]
17. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results]. Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. Mintz-Hittner HA; Kennedy KA; Chuang AZ; N Engl J Med; 2011 Feb; 364(7):603-15. PubMed ID: 21323540 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921 [TBL] [Abstract][Full Text] [Related]
20. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Lee JY; Chae JB; Yang SJ; Yoon YH; Kim JG Graefes Arch Clin Exp Ophthalmol; 2010 Sep; 248(9):1257-62. PubMed ID: 20393741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]